A Phase 3 interventional study of Facial Toner and Placebo Toner in Hyperpigmentation, sponsored by Good Molecules, LLC. Completed at 1 site in United States. Open to female participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Good Molecules, LLC · Phase 3, Interventional, and Treatment
The purpose of this study is to assess the efficacy (ability to produce a desired or intended result) of a topical product (applied to the skin) to improve skin lightness, skin condition and appearance (hyperpigmentation [dark spots], brightness/radiance [healthy vibrant appearance], skin texture [smoothness]) on ] the face over a period of eighteen (18) weeks. The data collected may support the company in developing marketing claims for its product.
127 studies on the registry are indexed under Hyperpigmentation; 28 are open to participants now.
This study's enrollment of 49 is above the median of 32 across 113 interventional studies indexed under Hyperpigmentation.
Browse Hyperpigmentation studies →Good Molecules, LLC is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Facial Toner
Other: Placebo Toner
Brightening Toner
Placebo Control Toner
Skin Lightness (L*)
L\* scale (lightness scale 0-100, 0 is black and 100 is white)
Time frame: 18 weeks
Erythema (a*)
a\* (red/green scale from -80 to 80; negative values are green and positive values are red. The more positive values, more redness)
Time frame: 18 weeks
Facial Hyperpigmentation
Analyzed by Expert Grading in a 10-point ordinal scale (0 = positive anchor of uniform, even appearance, and 9 = negative anchor of uneven, discolored, pigmentation present)
Time frame: 18 weeks
Facial Skin Texture
Analyzed by Expert Grading in a 10-point ordinal scale (0 = positive anchor of smooth, even surface appearance, and 9 = negative anchor of rough, uneven surface appearance)
Time frame: 18 weeks
Facial Brightness/Radiance
Analyzed by Expert Grading in a 10-point ordinal scale (0 = positive anchor of radiant, glowing appearance, and 9 = negative anchor of dull/lackluster)
Time frame: 18 weeks
Volunteer's Opinion on Product
Subjective Questionnaire with a Likert-scale (0 - disagree to 4 - agree)
Time frame: 18 weeks
Facial Skin Changes Via Images
Facial hyperpigmentation was assessed using the VISIA Complexion Analysis imaging system with Red/Brown (RBX) technology. Standardized frontal facial images were analyzed using automated image-processing software to quantify brown pigmentation features. The VISIA-CR RBX Brown Features score is a numerical, software-generated measurement of detected facial pigmentation rather than a count of individual brown spots. Higher scores indicate greater detected brown pigmentation (worse outcome), while lower scores indicate less pigmentation (better outcome). No theoretical minimum or maximum score has been established for this specific measurement. Results are reported as mean ± standard deviation (SD).
Time frame: 18 weeks
| Milestone | Test Product | Control Product |
|---|---|---|
| Started | 24 | 25 |
| Completed | 23 | 24 |
| Not completed | 1 | 1 |
| Withdrew: Personal | 1 | 1 |
L\* scale (lightness scale 0-100, 0 is black and 100 is white)
| L* - units on a scale | Test Product | Control Product |
|---|---|---|
| Baseline | 50.9 ± 9.7 | 56.1 ± 7.1 |
| Week_10 | 52.6 ± 9.9 | 58.1 ± 6.6 |
| Week_18 | 53.1 ± 10.0 | 58.2 ± 7.1 |
Analyzed by Expert Grading in a 10-point ordinal scale (0 = positive anchor of uniform, even appearance, and 9 = negative anchor of uneven, discolored, pigmentation present)
| Expert Grading - scores on a scale | Test Product | Control Product |
|---|---|---|
| Baseline | 5.7 ± 1.0 | 5.8 ± 0.9 |
| Week_10 | 5.0 ± 0.9 | 5.2 ± 0.9 |
| Week_18 | 4.8 ± 1.1 | 4.6 ± 0.9 |
Analyzed by Expert Grading in a 10-point ordinal scale (0 = positive anchor of smooth, even surface appearance, and 9 = negative anchor of rough, uneven surface appearance)
| Expert Grading - scores on a scale | Test Product | Control Product |
|---|---|---|
| Baseline | 5.3 ± 0.8 | 5.5 ± 0.9 |
| Week_10 | 4.7 ± 0.8 | 4.7 ± 0.7 |
| Week_18 | 4.6 ± 0.7 | 4.8 ± 1.0 |
Analyzed by Expert Grading in a 10-point ordinal scale (0 = positive anchor of radiant, glowing appearance, and 9 = negative anchor of dull/lackluster)
| Expert Grading - scores on a scale | Test Product | Control Product |
|---|---|---|
| Baseline | 5.6 ± 0.7 | 5.7 ± 1.0 |
| Week_10 | 4.6 ± 0.7 | 4.4 ± 0.7 |
| Week_18 | 4.3 ± 0.8 | 4.4 ± 0.7 |
Subjective Questionnaire with a Likert-scale (0 - disagree to 4 - agree)
| Likert-scale - units on a scale | Test Product | Control Product |
|---|---|---|
| My skin looked brighter after using the routine. | 2.0 ± 0.7 | 2.1 ± 0.8 |
| My skin looked less dull after using the routine. | 1.9 ± 0.5 | 2.0 ± 0.8 |
| My skin looked more radiant (healthy and vibrant) after using the routine. | 2.0 ± 0.7 | 2.1 ± 0.7 |
| My skin looked more youthful (appears young looking) after using the routine. | 2.3 ± 0.8 | 2.4 ± 0.8 |
| My skin tone (overall color of skin) looked more even after using the routine. | 2.1 ± 0.7 | 2.2 ± 0.8 |
| The pores on my face looked less visible after using the routine. | 2.3 ± 0.7 | 2.3 ± 0.8 |
| The dark spots on my face looked lighter after using the routine. | 2.0 ± 0.5 | 2.0 ± 0.8 |
| My skin felt smoother after using the routine. | 2.0 ± 0.6 | 1.9 ± 0.7 |
| My skin felt less oily after using the routine. | 1.9 ± 0.7 | 2.0 ± 0.8 |
| My skin felt softer after using the routine. | 1.9 ± 0.7 | 1.9 ± 0.7 |
| My skin felt tighter after using the routine. | 2.1 ± 0.7 | 2.3 ± 0.7 |
| I noticed a more refined (improved) skin texture after using the routine. | 2.3 ± 0.9 | 2.1 ± 0.7 |
| I noticed less discoloration on my skin after using the routine. | 2.2 ± 0.7 | 2.1 ± 0.8 |
| I noticed fewer blemishes (marks or imperfections on the skin) on my skin after using the routine. | 2.3 ± 0.9 | 2.3 ± 0.7 |
Facial hyperpigmentation was assessed using the VISIA Complexion Analysis imaging system with Red/Brown (RBX) technology. Standardized frontal facial images were analyzed using automated image-processing software to quantify brown pigmentation features. The VISIA-CR RBX Brown Features score is a numerical, software-generated measurement of detected facial pigmentation rather than a count of individual brown spots. Higher scores indicate greater detected brown pigmentation (worse outcome), while lower scores indicate less pigmentation (better outcome). No theoretical minimum or maximum score has been established for this specific measurement. Results are reported as mean ± standard deviation (SD).
| Scores on a scale | Test Product | Control Product |
|---|---|---|
| Baseline | 87.7 ± 23.0 | 93.4 ± 19.6 |
| Week_10 | 95.4 ± 29.3 | 104.7 ± 21.1 |
| Week_18 | 100.7 ± 28.5 | 108.1 ± 23.8 |
a\* (red/green scale from -80 to 80; negative values are green and positive values are red. The more positive values, more redness)
| a* - units on a scale | Test Product | Control Product |
|---|---|---|
| Baseline | 10.91 ± 1.91 | 11.08 ± 1.24 |
| Week_10 | 11.0 ± 1.86 | 11.13 ± 1.71 |
| Week_18 | 10.74 ± 1.78 | 10.67 ± 1.73 |
Collected over Up to 18 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Product | 0/23 (0%) | 0/23 (0%) | 1/23 (4.3%) |
| Control Product | 0/24 (0%) | 0/24 (0%) | 1/24 (4.2%) |
| Event | Test Product | Control Product |
|---|---|---|
| Closed Comedones and PustulesSkin and subcutaneous tissue disorders | 1/23 | 0/24 |
| Right Rotator Cuff RepairMusculoskeletal and connective tissue disorders | 0/23 | 1/24 |
There is one more participant in the control product group than in the test product group.
| Age, Continuous(years) | Test Product | Control Product | Total |
|---|---|---|---|
| Mean | 58.2 ± 8.7 | 57.2 ± 8.9 | 57.7 ± 8.7 |
| Sex: Female, Male(Participants) | Test Product | Control Product | Total |
|---|---|---|---|
| Female | 23 | 24 | 47 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Test Product | Control Product | Total |
|---|---|---|---|
| Asian | 2 | 4 | 6 |
| Black or African American | 8 | 1 | 9 |
| Hispanic or Latino | 3 | 4 | 7 |
| White | 10 | 15 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2025 to primary completion in Feb 2026, 5 months.
Results were first posted in Oct 2026, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Good Molecules, LLC